These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23076343)

  • 21. EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.
    Webb MI; Walsby CJ
    Metallomics; 2013 Dec; 5(12):1624-33. PubMed ID: 24057014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controversial Role of Transferrin in the Transport of Ruthenium Anticancer Drugs.
    Levina A; Chetcuti ARM; Lay PA
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. X-ray absorption near edge structure spectroscopy to resolve the in vivo chemistry of the redox-active indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019).
    Hummer AA; Heffeter P; Berger W; Filipits M; Batchelor D; Büchel GE; Jakupec MA; Keppler BK; Rompel A
    J Med Chem; 2013 Feb; 56(3):1182-96. PubMed ID: 23282017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Probing the stability of serum protein-ruthenium(III) drug adducts in the presence of extracellular reductants using CE.
    Timerbaev AR; Foteeva LS; Rudnev AV; Abramski JK; Połeć-Pawlak K; Hartinger CG; Jarosz M; Keppler BK
    Electrophoresis; 2007 Jul; 28(13):2235-40. PubMed ID: 17557359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma.
    Groessl M; Hartinger CG; Polec-Pawlak K; Jarosz M; Keppler BK
    Electrophoresis; 2008 May; 29(10):2224-32. PubMed ID: 18512673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ruthenium anticancer agent KP1019 binds more tightly than NAMI-A to tRNA
    Dwyer BG; Johnson E; Cazares E; McFarlane Holman KL; Kirk SR
    J Inorg Biochem; 2018 May; 182():177-183. PubMed ID: 29501978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding of an anticancer drug, axitinib to human serum albumin: Fluorescence quenching and molecular docking study.
    Tayyab S; Izzudin MM; Kabir MZ; Feroz SR; Tee WV; Mohamad SB; Alias Z
    J Photochem Photobiol B; 2016 Sep; 162():386-394. PubMed ID: 27424099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
    Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
    J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modification of multiwalled carbon nanotubes with a ruthenium drug candidate-indazolium[tetrachlorobis(1
    Richert M; Trykowski G; Walczyk M; Cieślak MJ; Kaźmierczak-Barańska J; Królewska-Golińska K; Sobczak JW; Biniak S
    Dalton Trans; 2020 Dec; 49(46):16791-16800. PubMed ID: 33174575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring the effect of the ligand design on the interactions between [Ru(η(5)-C5H5)(PPh3)(N,O)][CF3SO3] complexes and human serum albumin.
    Morais TS; Santos FC; Corte-Real L; Garcia MH
    J Inorg Biochem; 2013 Dec; 129():94-101. PubMed ID: 24096130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. En route to osmium analogues of KP1019: synthesis, structure, spectroscopic properties and antiproliferative activity of trans-[Os(IV)Cl4(Hazole)2].
    Büchel GE; Stepanenko IN; Hejl M; Jakupec MA; Keppler BK; Arion VB
    Inorg Chem; 2011 Aug; 50(16):7690-7. PubMed ID: 21739939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. X-ray fluorescence imaging of single human cancer cells reveals that the N-heterocyclic ligands of iodinated analogues of ruthenium anticancer drugs remain coordinated after cellular uptake.
    Antony S; Aitken JB; Vogt S; Lai B; Brown T; Spiccia L; Harris HH
    J Biol Inorg Chem; 2013 Oct; 18(7):845-53. PubMed ID: 23943098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies of KP46 and KP1019 and the Hydrolysis Product of KP1019 in Lipiodol Emulsions: Preparation and Initial Characterizations as Potential Theragnostic Agents.
    Pashkunova-Martic I; Losantos BC; Kandler N; Keppler B
    Curr Drug Deliv; 2018; 15(1):134-142. PubMed ID: 28000552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
    Thota S; Rodrigues DA; Crans DC; Barreiro EJ
    J Med Chem; 2018 Jul; 61(14):5805-5821. PubMed ID: 29446940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interactions of a novel ruthenium-based anticancer drug (KP1019 or FFC14a) with serum proteins--significance for the patient.
    Hartinger CG; Hann S; Koellensperger G; Sulyok M; Groessl M; Timerbaev AR; Rudnev AV; Stingeder G; Keppler BK
    Int J Clin Pharmacol Ther; 2005 Dec; 43(12):583-5. PubMed ID: 16372526
    [No Abstract]   [Full Text] [Related]  

  • 36. Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A).
    Heffeter P; Pongratz M; Steiner E; Chiba P; Jakupec MA; Elbling L; Marian B; Körner W; Sevelda F; Micksche M; Keppler BK; Berger W
    J Pharmacol Exp Ther; 2005 Jan; 312(1):281-9. PubMed ID: 15331656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors.
    Henke MM; Richly H; Drescher A; Grubert M; Alex D; Thyssen D; Jaehde U; Scheulen ME; Hilger RA
    Int J Clin Pharmacol Ther; 2009 Jan; 47(1):58-60. PubMed ID: 19203540
    [No Abstract]   [Full Text] [Related]  

  • 38. Binding mechanisms of half-sandwich Rh(III) and Ru(II) arene complexes on human serum albumin: a comparative study.
    Dömötör O; Enyedy ÉA
    J Biol Inorg Chem; 2019 Aug; 24(5):703-719. PubMed ID: 31300922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells.
    Kapitza S; Pongratz M; Jakupec MA; Heffeter P; Berger W; Lackinger L; Keppler BK; Marian B
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):101-10. PubMed ID: 15503135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin.
    Zhang Y; Ho A; Yue J; Kong L; Zhou Z; Wu X; Yang F; Liang H
    Eur J Med Chem; 2014 Oct; 86():449-55. PubMed ID: 25200980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.